Purpose: To evaluate the efficacy of intralesional bevacizumab injection in decreasing size of pterygium.
P
terygium is a common ocular disorder with different reported prevalence rates ranging from 0.3% to 29% in different parts of the world. 1, 2 The treatment of choice for pterygium is surgical excision, which includes simple excision (the bare sclera technique) and excision with grafting (conjunctival or amniotic membrane grafts). 3 To prevent recurrence of the pterygium, several studies have evaluated the efficacy of adjunctive therapies, like b-radiation, mitomycin C (MMC), 5-fluorouracil (5-FU), and corticosteroids, together with simple excision. 4, 5 However, these methods could have unwilling side effects like punctate epitheliopathy, bacterial superinfection, delayed onset scleral melting, and rise in intraocular pressure.
Several active angiogenic and epithelial growth factors such as basic fibroblast growth factor, heparin-binding epidermal growth factor, connective tissue growth factor, and vascular endothelial growth factor (VEGF) have been shown to be significantly increased in pterygium, suggesting that growth factors may be involved directly or indirectly in its pathogenesis. 6, 7 However, the most prominent of these factors is VEGF, which is the main target of many current antiangiogenic therapies. 8 Bevacizumab (Avastin; Genentech, South San Francisco, CA) is a monoclonal antibody to VEGF A that binds to both VEGF receptors VEGFR2 and VEGFR1 and inhibits both receptors. 9, 10 There are several studies to evaluate the efficacy of bevacizumab (Avastin) in regression of the corneal neovascularization, [11] [12] [13] but the use of Avastin as an adjunct in the treatment of pterygium is scarce. Herein, we report our experience in evaluation of the efficacy of intralesional injection of bevacizumab in decreasing the size of pterygium.
PATIENTS AND METHODS
Seventeen consecutive patients with pterygium (14 with primary and 3 patients with recurrent pterygium) were enrolled. Informed consents were obtained from all patients before enrollment. The study was approved by Farabi Eye Hospital Ethics Committee. Patients were examined before injection and, in each visit, at 1 week, 1 month, and 3 months after injection, including visual acuity, slit-lamp examination, indirect ophthalmoscope funduscopy, and applanation tonometry. The platelet count and blood pressure were also measured.
Patients underwent injection of 2.5 mg/0.1 mL of bevacizumab into the base of the pterygium with a 25-gauge needle in the operating room and under the microscope. Two patients of primary cases and 1 patient of recurrent pterygium received a second subconjunctival injection. Patients with a history of myocardial infarction and vascular thrombosis in the last 6 months were excluded.
At each visit and before treatment, photographs were taken from corneal surface with 316 magnifications using a Nikon digital camera attached to the slit-lamp microscope. Corneal involvements were measured on the digital photographs as the percentage of the total area of the cornea. Image analysis was performed using an image processing and analysis software program (Image J 1.37 v; Wayne Rasband at the Research Services Branch, National Institute of Mental Health, Bethesda, MD). All measurements and analyses were performed by a person who was unaware to the study and medications.
Statistical analysis was performed by using SPSS (version 13; SPSS, Chicago, IL). Student t test was used for continuous variables, and P values less than 0.05 were considered significant. Data were expressed as mean 6 SD.
RESULTS
The study group included 17 eyes of 17 patients, 14 patients with primary pterygium and 3 patients with recurrent pterygium. The demographic data of the patients is shown in Table 1 . The mean percentage size of lesions before injection was 17.2% 6 4.3%. The mean percentage size of lesions 1 week, 1 month, and 3 months after injection was 15.1% 6 4.3%, 13.4% 6 4.0%, and 14.1% 6 4.4%, respectively. The mean percentage decrease size of lesion in primary cases was 3.970% 6 3.843% (range: 0.04%-14.47%) ( Table 2) .
However, in recurrent cases, progression was observed. The mean percentage of progression of the size of corneal involvement in recurrent cases was 1.11% 6 0.450% (range: 0.6%-1.44%). There were significant differences between percentage size of lesion before injection and 1 week (P , 0.001), 1 month (P , 0.001), and 3 months (P , 0.001) after injection.
Visual acuity, blood pressure, intraocular pressure, and platelet count did not change significantly in any patient before injection and in the end of study. The only complication was subconjunctival hemorrhage in 3 patients, which was resolved after 1 week.
DISCUSSION
Pterygia, defined as a degenerative disorder, may be associated with chronic exposure to sunlight; however, their formation and progression are known to depend on neovascularization. 7, 14 The process of angiogenesis is normally mediated by a balance between angiogenic stimulators and angiogenic inhibitors. 15 It has also been suggested that the development of pterygia depends on a changed angiogenic stimulator-inhibitor ratio. Pterygium tissues contain decreased levels of angiogenic inhibitors such as pigment epitheliumderived factor, whereas they contain increased VEGF levels. 7 Gebhardt et al 6 reported that VEGF is increased in pterygia in comparison with that in healthy human conjunctiva.
Recent studies report successful outcomes after administration of bevacizumab for the treatment of corneal neovascularization. Erdurmus et al 16 evaluated the efficacy of subconjunctival bevacizumab injection (2.5 mg/0.1 mL) in 2 patients with corneal neovascularization and different etiologies: one patient with dry eye, whose vessels significantly regressed a week after the injection, but the other patient with a failed graft, who had only a minor vessels regression. Awadein 17 described 3 patients with corneal neovascularization after keratoplasty treated with a single subconjunctival Review of the literature shows that there are few reports of administering of bevacizumab in the treatment of recurrent pterygia with different route of administering (intralesional injection or topical) with some controversies. Bahar et al 18 reported the effect of subconjunctival bevacizumab on corneal vessel density in recurrent pterygia in 5 patients. None of them demonstrated any significant clinical regression of vessels. There are 2 studies in favor of use of bevacizumab for decreasing the size of pterygium. Mansour 19 presented 2 cases with inflamed residual pterygial bed unresponsive to topical antiinflammatory therapy and 1 case with inflamed pterygium underwent intralesional injections (followed for 1 month-1.5 year). The inflammation was promptly controlled by subconjunctival anti-VEGF. In another report, Teng et al investigated the effect of subconjunctival bevacizumab on primary pterygium. They described a patient with an inflamed nasal primary pterygium, refractory to topical medications. Bevacizumab (1.25 mg/0.05 mL) was injected subconjunctivally near the limbus. They found that 1 week after procedure, irritation and hyperemia regressed. At week 2, the pterygium maintained this appearance. After 7 weeks of follow-up, the degree of vascularization and symptoms of irritation regressed to its preinjection state. 20 There are 2 reports suggesting use of topical bevacizumab. Wu et al 21 reported a patient with impending recurrent pterygium treated with topical bevacizumab eyedrops (25 mg/mL) administered 4 times daily for 3 weeks. Treatment prominently decreased limbal-conjunctival neovascularization. At 6-month follow-up, no recurrent pterygium was noted, and slit-lamp examination revealed no adverse ocular effects. Also, Leippi et al 22 reported use of bevacizumab eyedrops to prevent recurrence of pterygia in 5 eyes (4 patients) treated with topical bevacizumab eyedrops (25 mg/mL) 2-8 times per day for 5-24 weeks as an adjunct after excision of recurrent pterygia and conjunctival autograft. Patients were examined preoperatively and over a follow-up period ranging from 3 to 14 months. Two eyes showed conjunctival hyperemia (stage 1 recurrence), 1 eye showed fibrosis of the limbus (stage 2 recurrence), 1 eye an early recurrence (stage 3 recurrence), and in 1 eye no pterygium recurrence was noted. They proposed the use of topical VEGF inhibitors in recurrent pterygia. In our study, the percentage size of vascularized cornea significantly decreased at the end of 3-month follow-up; however, corneal haziness was still present to some extent.
All of these studies are preliminary and with low sample size of patients. The promising point of view is that in these studies, there was no reported adverse effect for bevacizumab. The important question is to quantify the therapeutic concentrations of such antibodies in the cornea. It is postulated that for control of corneal neovascularization, higher doses of bevacizumab than the classic 2.5-mg dosage given in intravitreal injections may be needed for subconjunctival injections.
In conclusion, intralesional bevacizumab is well tolerated and the percentage size of vascularized cornea showed a statistically significant decrease at the end of 3-month follow-up and fibrovascular lesion in patients with primary pterygium did not progress. Despite statistically significant decrease in pterygium size, a decrease of 4% in the pterygium size does not seem to be clinically significant. However, repeated injection of bevacizumab (to decrease the pterygium size more efficiently) or its adjuvant role before or during surgical removal of pterygium may help to address its clinical significance in future studies.
